TARGET AUDIENCE

This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with acute respiratory infections.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the role of IL-33 in the pathophysiology of COPD, acute viral respiratory infections, and other respiratory conditions
• Summarize current clinical trial data on the efficacy and safety of anti-IL-33/ST2 therapies for the treatment of COPD, acute viral respiratory infections, and other respiratory conditions
• Utilize current clinical trial evidence to identify patients who may be suitable candidates for treatment with anti-IL-33/ST2 therapies if and when they become available

FACULTY

	Gerard J. Criner, MD, FACP, FACCP Chair and Professor Thoracic Medicine and Surgery Lewis Katz School of Medicine Director, Temple Lung Center Temple University Philadelphia, Pennsylvania
	Nicola A. Hanania, MD, MS, FCCP, FACP, FRCP(C), FERS Professor of Medicine, Section of Pulmonary and Critical Care Medicine Director, Airways Clinical Research Center Baylor College of Medicine Chief, Section of Pulmonary and Critical Care Medicine Ben Taub Hospital Houston, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Gerard J. Criner, MD, FACP, FACCP 
Consultant: Apreo, AstraZeneca, Boehringer Ingelheim, GSK, Olympus, Pulmonx, Sanofi/Regeneron

Nicola A. Hanania, MD, MS, FCCP, FACP, FRCP(C), FERS
Advisor/Consultant: AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Sanofi/Regeneron
Research Grant Support (to institution): American Lung Association, AstraZeneca, Genentech, GSK, National Heart, Lung, & Blood Institute, Sanofi

The Integrity CE, LLC planners and managers do not have any relevant financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 6, 2024 through December 6, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 20, 2024
Expiration date: February 20, 2025
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi.

PROGRAM OVERVIEW

he treatment of myeloma has changed dramatically over the last decade, including integration of a gentler approach and an emphasis on achieving deep and durable responses to primary therapy. Today, anti-CD38 monoclonal antibody (mAb)-based quadruplet therapy is a standard of care. New data on quadruplet regimens offer more therapeutic options to patients. Additionally, the roles of minimal residual disease (MRD) assessment in multiple myeloma have been developing. This clinical reviews methods for MRD assessment and offers expert perspectives on its use in clinical practice.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologists, advance practice professionals, and nurses who treat and manage patients with multiple myeloma.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Appraise the clinical implications of recent anti-CD38 antibody studies for patients with multiple myeloma

FACULTY CHAIR

Saad Z. Usmani, MD, MBA, FACP  Chief, Myeloma Service Memorial Sloan Kettering Cancer Center (MSK) Member, Memorial Sloan Kettering Cancer Center Attending Physician, Myeloma, Cellular Therapy and Adult BMT Memorial Sloan Cancer Center New York, New York

FACULTY DISCUSSANTS

Rahul Banerjee, MD, FACP Assistant Professor, Clinical Research Division Fred Hutchinson Cancer Center Seattle, Washington

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Rahul Banerjee, MD, FACP
Consultant: Adaptive, Bristol Myers Squibb, Caribou, Genentech, GlaxoSmithKline, Johnson and Johnson, Karyopharm Legend, Sanofi
Research: AbbVie, Bristol Myers Squibb, Johnson and Johnson, Novartis, Pack Health, Prothena, Sanofi

Saad Z. Usmani, MD, MBA, FACP, FRCP, FASCO
Consultant: AbbVie, Amgen, Bristol Myers Squibb, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura
Research: Amgen, Array Biopharma, Bristol Myers Squibb, EdoPharm

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2024 through February 20, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 20, 2024
Expiration date: December 20, 2025
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

PROGRAM OVERVIEW

TBD

TARGET AUDIENCE

This educational activity has been designed to meet the needs of US-based psychiatrists, primary care and internal medicine physicians, and other clinicians who specialize in managing patients with schizophrenia, including nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Explain the differences between positive, negative, and cognitive symptoms associated with schizophrenia
• Discuss the key neurotransmitters that are thought to be involved in the pathophysiology of negative symptoms and cognitive impairment associated with schizophrenia (CIAS)
• Integrate emerging therapeutics, after FDA approval, into treatment options for schizophrenia based on recent clinical trial findings

FACULTY

Daniel C. Javitt, MD, PhD Professor and Director, Division of Experimental Therapeutics Department of Psychiatry Columbia University Irving Medical Center New York, New York Director, Schizophrenia Research

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Daniel C. Javitt, MD, PhD
Consultant: SK Life Science
Internal Speaker: Boehringer Ingelheim
Major Shareholder: NRx Pharmaceuticals
Monitoring Board Member: Biogen

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 20, 2024 through December 20, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 27, 2024
Expiration date: November 27, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

During this interactive webcast, our esteemed faculty will discuss unmet needs in the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Key topics will include patient evaluation, treatment planning and patient selection criteria for surgical or biologic treatment, and strategies for the appropriate use of biologics in patients with CRSwNP.

TARGET AUDIENCE

This educational activity has been designed for US otolaryngologists, otolaryngic allergists, and otolaryngology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Accurately evaluate disease severity in patients with CRSwNP
• Create treatment plans that implement appropriate biologic or surgical treatment options for patients with CRSwNP
• Describe strategies to overcome barriers to effective use of biologic therapies in the treatment of appropriate patients with CRSwNP

FACULTY

	Joseph K. Han, MD, FARS, FAAOA Professor of Otolaryngology Sentara Norfolk General Hospital – River Pavillion Vice Chair Eastern Virginia Medical School Old Dominion University Norfolk, Virginia
	Stella Lee, MD Section Chief Rhinology Brigham and Women’s Hospital Harvard Medical School Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Joseph K. Han, MD, FARS, FAAOA
Research Consultant: AstraZeneca, Glaxo Smith Kline, Regeneron, Sanofi

Stella Lee, MD
Consultant: AstraZeneca, Genentech, Glaxo Smith Kline, Lyra Therapeutics, Optinose, Regeneron, Sanofi
Equity: Diceros Therapeutics

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 26, 2024 through November 26, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 70% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 7, 2024
Expiration date: November 7, 2025
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity CE, LLC.
This CE activity for ANCC and AANP credit is jointly provided by Global Education Group and Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Merck Sharp & Dohme, LLC.

PROGRAM OVERVIEW

It’s still a deadly disease and there’s still no cure, but with treatment, survival for patients with pulmonary arterial hypertension (PAH) can be significantly extended. Although rare, nurse practitioners are likely to encounter this cardiopulmonary disorder throughout their careers, and need to be familiar with the multiple drug classes and combinations thereof that are used to target the molecular drivers of this disease. They will also need to be able to recognize PAH in patients they might never suspect of having this disease, namely children and adults exposed to illicit stimulant drugs.

Premiere clinical guidelines on diagnosing and managing PAH were recently updated and in March 2024, two new treatment choices were approved by the FDA — a first-in-class add-on treatment that can enhance therapeutic response and a fixed-dose, single-tablet combination of the two drug classes that the guidelines recommend as initial treatment for most patients. Join PAH expert Dr. John J. Ryan for this Nurse Practitioners’ Summit special course on recent guideline changes, newly approved treatments, and more.

TARGET AUDIENCE

This activity is designed for nurse practitioners, nurses, and physician assistants who manage patients with or at risk for PAH.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Discuss recently published recommendations for diagnosing and managing PAH
• Summarize ways to identify and manage children with PAH and adults with methamphetamine-associated PAH
• Describe how to include new therapies into treatment and monitoring strategies based on efficacy and safety findings from clinical trials

FACULTY

John J. Ryan, MD, MB, BCh, BAO Professor, University of Utah Director, Pulmonary Hypertension Comprehensive Care Center Director, Cardiovascular Medicine Fellowship Program Chief of General Cardiology University of Utah School of Medicine Salt Lake City, Utah

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

John J. Ryan, MD, MB, BCh, BAO  
Advisor, researcher, speaker for: Bayer, Johnson & Johnson, Kiniksa Pharmaceuticals, Merck, United Therapeutics

The Integrity CE, LLC and Global Education Group planners and managers do not have any relevant financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of November 7, 2024 through November 7, 2025 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION

Physician Continuing Education

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity CE, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour(s) (which includes 0.1 hour(s) of pharmacology).

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.75 contact hour including 0.0 pharmacotherapeutic contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

For information about AANP and ANCC approval of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: October 30, 2024
Expiration date: January 30, 2025
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi.

PROGRAM OVERVIEW

The treatment of myeloma has changed dramatically over the last decade, including integration of a gentler approach and an emphasis on achieving deep and durable responses to primary therapy. Today, anti-CD38 monoclonal antibody (mAb)-based quadruplet therapy is a standard of care. New data on quadruplet regimens offer more therapeutic options to patients. This clinical brief reviews recent results from the phase 3 PERSEUS and IsKia clinical trials of anti-CD38 mAb-based quadruplet therapy for patients with newly diagnosed multiple myeloma who are eligible for transplant. The clinical relevance of these results will be discussed.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologists, advance practice professionals, and nurses who treat and manage patients with multiple myeloma.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Appraise the clinical implications of recent anti-CD38 antibody studies for patients with multiple myeloma

FACULTY CHAIR

Saad Z. Usmani, MD, MBA, FACP  Chief, Myeloma Service Memorial Sloan Kettering Cancer Center (MSK) Member, Memorial Sloan Kettering Cancer Center Attending Physician, Myeloma, Cellular Therapy and Adult BMT Memorial Sloan Cancer Center New York, New York

FACULTY DISCUSSANTS

	Rahul Banerjee, MD, FACP Assistant Professor, Clinical Research Division Fred Hutchinson Cancer Center Seattle, Washington
	Surbhi Sidana, MD Associate Professor of Medicine Stanford University Stanford, California

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Rahul Banerjee, MD, FACP
Consultant: Adaptive, Bristol Myers Squibb, Caribou, Genentech, GlaxoSmithKline, Johnson and Johnson, Karyopharm Legend, Sanofi
Research: AbbVie, Bristol Myers Squibb, Johnson and Johnson, Novartis, Pack Health, Prothena, Sanofi

Surbhi Sidana, MD
Advisory Boards: AbbVie, BiolineRx, Bristol Myers Squibb, Janssen, Legend, Magenta Therapeutics, Oncopeptides, Pfizer, Regeneron, Sanofi, Takeda
Consultant: Abbvie, BiolineRx, Bristol Myers Squibb, Janssen, Legend, Oncopeptides, Pfizer, Regeneron, Sanofi, Takeda
Research: Allogene, Bristol Myers Squibb, Janssen, Magenta Therapeutics, Novartis

Saad Z. Usmani, MD, MBA, FACP, FRCP, FASCO
Consultant: AbbVie, Amgen, Bristol Myers Squibb, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura
Research: Amgen, Array Biopharma, Bristol Myers Squibb, EdoPharm

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 30, 2024 through January 30, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 16, 2024
Expiration date: December 16, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

Rashes…pediatric nurse practitioners (PNPs) see them all the time. However, atopic dermatitis (AD), also known as eczema, is not just any rash. It is a disease caused by an inflammatory immune response that affects much more than just the skin. It can have severe, lifelong consequences in all aspects of children’s lives. Fortunately, there are now many effective treatments for even the most severe cases and youngest children — down to 6 months of age. This gives PNPs an important role to play in the therapeutic management of infants, children, and adolescents who are affected by AD. Join pediatric AD expert Dr. Peter Lio for the latest advancements in treatment, curated specifically for PNPs.

TARGET AUDIENCE

This educational activity is designed for pediatric nurse practitioners and other healthcare providers involved in managing care for children and adolescents with AD, including primary care physicians, family physicians, and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Delineate the role of pediatric nurse practitioners in diagnosing and managing AD
• Differentiate between AD severity levels to determine which patients may need referral to a specialist
• Develop practical strategies for enhancing adherence to and monitoring of treatments for AD that are FDA approved specifically for pediatric populations

FACULTY

Peter Lio, MD, FAAD Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai Clinical Assistant Professor of Dermatology & Pediatrics Northwestern University Feinberg School of Medicine Founding Director, Chicago Integrative Eczema Center Founding Partner, Medical Dermatology Associates of Chicago Chicago, Illinois

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Peter Lio, MD, FAAD
Advisory Boards: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KPAway), Burt’s Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, LEO, Level Ex, Lipidor AB, L’Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, YobeeCare
Patent Holder: Theraplex AIM (patent pending)
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Speaker: AbbVie, Eli Lilly, Galderma, Incyte, LEO, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme
Stock Options: Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences, LearnSkin, Micreos, YobeeCare

The Integrity CE, LLC and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 16, 2024 through December 16, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: October 24, 2024
Expiration date: October 24, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

During this case-based interactive video, our esteemed faculty will discuss strategies to improve the care of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Key topics will include patient evaluation, selection criteria for surgical or biologic treatment, and current evidence on comparative safety and efficacy of available treatments.

TARGET AUDIENCE

This activity addresses the needs of allergists, otolaryngologists, nurse practitioners, and physician assistants involved in the management of patients with CRSwNP.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Effectively assess severity in patients with CRSwNP
• Select appropriate biologic or surgical treatment options for patients with CRSwNP based on available efficacy and safety data
• Implement strategies for the effective use of biologic therapies in the treatment of appropriate patients with CRSwNP and to overcome barriers to successful treatment

FACULTY

	Christine Franzese, MD Professor of Clinical Otolaryngology Director of Allergy Department of Otolaryngology – Head and Neck Surgery University of Missouri Columbia, Missouri
	Joseph K. Han, MD Professor of Medicine Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery Chief, Division of Allergy Eastern Virginia Medical School Norfolk, Virginia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Christine Franzese, MD
Research Support: AstraZeneca, Eli Lilly, GlaxoSmithKline, Lyra, Regeneron, Sanofi, Upstream Bio
Speakers’ Bureau: AstraZeneca, GlaxoSmithKline, Optinose, Regeneron, Sanofi

Joseph K. Han, MD
Research Consultant: AstraZeneca, GlaxoSmithKline, Sanofi Regeneron

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 24, 2024 through October 24, 2025 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: October 1, 2024
Expiration date: October 1, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Primary care providers are on the front lines of managing asthma. They play a crucial role in identifying uncontrolled asthma and considering biologic therapies as alternatives to high-dose inhaled corticosteroids or oral medications. This can significantly reduce the disease burden. However, biologics aren’t a one-size-fits-all solution. Careful selection and individualization are essential, and a multidisciplinary approach is highly beneficial. Effective referral pathways and strong communication and collaboration between primary care providers and specialists are now more critical than ever.

Join our esteemed faculty as they discuss assessing asthma control, indicators for and evidence supporting biologics, and strategies for optimal patient evaluation and co-management through effective referrals and communication.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of family medicine physicians, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with asthma.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Identify clinical indicators of uncontrolled asthma and candidates who may benefit from addition of biologic therapy to treatment plans
• Discuss available biologic therapies for asthma management, data supporting their clinical use, and initiation criteria
• Describe multispecialty management strategies for patients with asthma including the critical importance of referral for respiratory specialist evaluation

FACULTY

	Nicola Hanania, MD, MS Associate Professor of Pulmonary Medicine Director, Airways Clinical Research Center Baylor College of Medicine Houston, Texas
	Tara F. Carr, MD Physician Professor of Medicine, University of Arizona Banner University Medical Center Tucson, Arizona

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Tara F. Carr, MD, MS
Author/Peer Reviewer: Wolters Kluwer (UpToDate)
Speaker: GlaxoSmithKline

Nicola Hanania, MD
Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Regeneron, Sanofi
Research Grant Support to Institution: AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Sanofi

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2024 through October 1, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 20, 2024
Expiration date: December 20, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Scientific Affairs, LLC and Seagen, Inc.

PROGRAM OVERVIEW

There is no clear standard-of-care treatment for patients with metastatic urothelial carcinoma following progression on enfortumab vedotin and pembrolizumab, although multiple regimens are available, including platinum-based chemotherapy, sacituzumab govitecan, and erdafitinib for selected patients. This case focuses on a patient with FGFR3 wild-type, HER2 IHC 2+, metastatic urothelial cancer following progression on enfortumab vedotin plus pembrolizumab.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical and surgical oncologists, urologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in treatment and management of patients with genitourinary cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select personalized treatments for patients with genitourinary malignancies based on disease and patient characteristics

FACULTY

	Shilpa Gupta, MD Director, Genitourinary Oncology Hematology and Oncology Department Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
	Jonathan Anker, MD, PhD Clinical and Research Fellow Department of Hematology and Medical Oncology The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Jonathan Anker, MD, PhD does not have any financial relationships or relationships to products or devices with ineligible companies.

Shilpa Gupta, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 20, 2024 through December 20, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 18, 2024
Expiration date: September 18, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is jointly provided by Integrity CE, LLC and Unbiased Science LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from CSL Seqirus.

PROGRAM OVERVIEW

The overarching goals of this activity are to address potential gaps in clinician knowledge and improve clinician confidence to recommend and administer flu vaccines (ultimately improving the uptake of flu vaccines in the population). This program focuses on commonly asked questions about the flu vaccine with a goal of helping healthcare providers communicate effectively to reduce vaccine hesitancy.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pharmacists and primary care physicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Increase knowledge and understanding of flu vaccination
• Increase knowledge of available vaccine technologies
• Improve their ability to educate their patients about the benefits of flu vaccination

FACULTY

Jessica Steier, DrPH, MPH, PMP Public Health Scientist CEO, Vital Statistics Consulting Founder & Host, Unbiased Science Pelham, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Jessica Steier, DrPH, MPH, PMP
Consultant: Moderna
Grant for Educational Materials: CSL Seqirus

The Integrity CE, LLC and Unbiased Science LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 18, 2024 through September 18, 2025 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Integrity CE, LLC and Unbiased Science LLC. Integrity CE, LLC is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 18, 2024
Expiration date: September 18, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is jointly provided by Integrity CE, LLC and Unbiased Science LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from CSL Seqirus.

PROGRAM OVERVIEW

The overarching goals of this activity are to address potential gaps in clinician knowledge and improve clinician confidence to recommend and administer flu vaccines (ultimately improving the uptake of flu vaccines in the population), particularly for special populations. This program will focus on key considerations for pregnant and breastfeeding individuals, travelers, children, the elderly, healthcare workers, and others.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pharmacists and primary care physicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Enhance knowledge of flu vaccination and key considerations for special populations
• Increase knowledge and understanding of flu vaccination
• Increase knowledge of available vaccine technologies
• Improve their ability to educate their patients about the benefits of flu vaccination

FACULTY

Jessica Steier, DrPH, MPH, PMP Public Health Scientist CEO, Vital Statistics Consulting Founder & Host, Unbiased Science Pelham, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Jessica Steier, DrPH, MPH, PMP
Consultant: Moderna
Grant for Educational Materials: CSL Seqirus

The Integrity CE, LLC and Unbiased Science LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 18, 2024 through September 18, 2025 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Integrity CE, LLC and Unbiased Science LLC. Integrity CE, LLC is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 17, 2024
Expiration date: September 17, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is jointly provided by Integrity CE, LLC and Unbiased Science LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from CSL Seqirus.

PROGRAM OVERVIEW

The overarching goals of this activity are to address potential gaps in clinician knowledge and improve clinician confidence to recommend and administer flu vaccines (ultimately improving the uptake of flu vaccines in the population). This program will examine the safety and efficacy of flu vaccines, addressing common misconceptions and other concerns held by patients and healthcare providers alike.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pharmacists and primary care physicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Improve their ability to address concerns raised by patients regarding the safety and
  effectiveness of flu vaccines
• Improve their ability to educate their patients about the benefits of flu vaccination

FACULTY

Jessica Steier, DrPH, MPH, PMP Public Health Scientist CEO, Vital Statistics Consulting Founder & Host, Unbiased Science Pelham, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Jessica Steier, DrPH, MPH, PMP
Consultant: Moderna
Grant for Educational Materials: CSL Seqirus

The Integrity CE, LLC and Unbiased Science LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 17, 2024 through September 17, 2025 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Integrity CE, LLC and Unbiased Science LLC. Integrity CE, LLC is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 16, 2024
Expiration date: September 16, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is jointly provided by Integrity CE, LLC and Unbiased Science LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from CSL Seqirus.

PROGRAM OVERVIEW

The overarching goals of this activity are to address potential gaps in clinician knowledge and improve clinician confidence to recommend and administer flu vaccines (ultimately improving the uptake of flu vaccines in the population). This program will provide an overview of what the flu vaccine is, what it does, and how it works. By breaking down the science of vaccination in the case of flu vaccines, the aim is to demystify the vaccination process and ease the concerns of those hesitant to receive them because of anxiety or misinformation.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pharmacists and primary care physicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Increase their knowledge and understanding of flu vaccination among a variety of healthcare
  providers
• Increase their knowledge of available vaccine technologies
• Improve their ability to educate their patients about the benefits of flu vaccination

FACULTY

Jessica Steier, DrPH, MPH, PMP Public Health Scientist CEO, Vital Statistics Consulting Founder & Host, Unbiased Science Pelham, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Jessica Steier, DrPH, MPH, PMP
Consultant: Moderna
Grant for Educational Materials: CSL Seqirus

The Integrity CE, LLC and Unbiased Science LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 16, 2024 through September 16, 2025 participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Integrity CE, LLC and Unbiased Science LLC. Integrity CE, LLC is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 16, 2024
Expiration date: September 16, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

With the accelerated expansion of the treatment landscape of intermediate and advanced hepatocellular carcinoma (HCC), several practical challenges have emerged in clinical practice. An example of this is the challenge of identifying patients with intermediate HCC who would benefit from local-regional treatment with TACE/TARE or a combination approach with TACE/TARE + IO. Multidisciplinary care is critical to optimize outcomes for these patients.

This program features a moderated discussion among a panel of experts: a surgeon, a hepatologist, and a medical oncologist, all involved in the management and treatment of patients with HCC.

TARGET AUDIENCE

This educational activity has been designed to meet the professional educational needs of medical, surgical, and radiation oncologists, gastroenterologists, interventional radiologists, and advanced practice professionals who treat and manage patients with gastrointestinal cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Implement novel first-line regimens, including multimodal combination and sequential treatment strategies, in the treatment of patients with intermediate HCC based on emerging evidence from clinical trials
• Integrate emerging therapies and novel combination regimens in the treatment of patients with advanced HCC to improve treatment outcomes

FACULTY

MODERATOR

Michael Pishvaian, MD, PhD  Director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital Johns Hopkins University School of Medicine Washington, District of Columbia

PANEL

Richard S. Finn, MD Professor of Medicine, Hematology/Oncology Geffen School of Medicine at UCLA Director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California

Riad Salem, MD Professor of Radiology, Medicine, and Surgery Vice-Chair, Image-Guided Therapy Chief, Vascular and Interventional Radiology Northwestern University Chicago, Illinois

Amit Singal, MD, MS Professor of Medicine Chief of Hepatology and Director of Liver Tumor Program UT Southwestern Medical Center Dallas, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Richard S. Finn, MD
Consultant: AstraZeneca, Bayer, CStone, Eisai, Eli Lilly, Exelixis, Merck, Novartis, Pfizer, Roche/Genentech, Zai Labs
Research Grants: Bayer, Eisai, Eli Lilly, Pfizer, Merck, Roche/Genentech

Michael Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Steering Committees: Astellas, Merck, Renovo Rx
CME Activity: Astellas
Travel: Astellas, Renovo Rx
Stock: Perthera

Riad Salem, MD
Consultant: AstraZeneca, Becton Dickinson, Boston Sciences, Cook, Eisai, Genentech, Siemens, Sirtex, Terumo

Amit Singal, MD, MS
Consultant: AstraZeneca, Bayer, Boston Scientific, Eisai, Exact Sciences, Exelixis, FujiFilm Medical Sciences, Glycotest, HistoSonics, Merck Genentech, Sirtex

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 16, 2024 through September 16, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 6, 2024
Expiration date: December 6, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from AstraZeneca, Lilly, Novartis, and Seagen, Inc.

PROGRAM OVERVIEW

Judith, a 57-year-old post-menopausal woman, is diagnosed with HR+, HER2+ (IHC3+ FISH ratio 11) metastatic breast cancer. She receives frontline THP (taxane, trastuzumab, and pertuzumab) and now presents with central nervous system (CNS) progression despite stereotactic radiosurgery (SRS). Which treatment will you choose?

Trials discussed include: EMILIA, DESTINY-Breast03, HER2CLIMB, and HER2CLIMB-02.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in treatment and management of patients with breast cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Individualize therapeutic regimens based on the molecular profile of tumors and patient characteristics
• Implement supportive care strategies to mitigate and manage unique toxicities associated with recently approved and emerging targeted therapies

FACULTY

	Laura Huppert, MD Assistant Professor University of California San Francisco, California
	Kelsey Natsuhara, MD Hematology & Oncology Fellow University of California San Francisco, California

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Laura Huppert, MD
Advisory Boards: AstraZeneca, Pfizer

Kelsey Natsuhara, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 6, 2024 through December 6, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: August 16, 2024
Expiration date: November 16, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Scientific Affairs, LLC and Seagen, Inc.

PROGRAM OVERVIEW

This case will focus on a 69-year-old male who presents with lower back pain and urinary dribbling. His total PSA is elevated at 58 ng/mL. The physical exam showed a KPS of 80, with no other significant findings. He has a history of atrial fibrillation. A bone scan reveals diffuse metastases, while CT shows liver lesions and an enlarged prostate. TRUS-guided biopsy confirms prostate adenocarcinoma with a Gleason score of 9 (5+4).

Treatment options discussed include doublet and triplet therapy combinations.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical and surgical oncologists, urologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in treatment and management of patients with genitourinary cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select personalized treatments for patients with genitourinary malignancies based on disease and patient characteristics

FACULTY

	Yüksel Ürün, MD Professor of Medicine Ankara University School of Medicine Department of Medical Oncology Ankara, Turkey
	Emre Yekedüz, MD Medical Oncologist Research Fellow Dana-Farber Cancer Institute Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Yüksel Ürün, MD
Consultation: Astellas, Bristol Myers Squibb, GlaxoSmithKline Pharmaceuticals, Janssen, Merck, MSD, Pfizer

Emre Yekedüz, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 16, 2024 through November 16, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: August 23, 2024
Expiration date: November 23, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from AstraZeneca, Lilly, Novartis, and Seagen, Inc.

PROGRAM OVERVIEW

This case will focus on a 68-year-old postmenopausal woman who presents with new palpable axillary lymphadenopathy and severe back pain. After workup and testing, she receives a diagnosis of HR+, HER2- metastatic breast cancer.

The discussion will cover the selection of the optimal treatment from the available Cyclin-dependent kinase 4 and 6 (CDK 4/6i) combinations. Trials included are MONARCH-3, PALOMA-2, and MONALEESA-2.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in treatment and management of patients with breast cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Individualize therapeutic regimens based on the molecular profile of tumors and patient characteristics
• Implement supportive care strategies to mitigate and manage unique toxicities associated with recently approved and emerging targeted therapies

FACULTY

	Yara Abdou, MD Assistant Professor Breast Medical Oncologist University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
	Prarthna Bhardwaj, MD, FACP Fellow University of Massachusetts Chan Medical School – Baystate Springfield, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Yara Abdou, MD
Advisor: AstraZeneca
Consultant: Exact Sciences

Prarthna Bhardwaj, MD, FACP does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 23, 2024 through November 23, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: August 2, 2024
Expiration date: November 2, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Scientific Affairs, LLC and Seagen, Inc.

PROGRAM OVERVIEW

This case will focus on a 68-year-old man with FGFR3 S249C mutation-positive metastatic urothelial cancer (mUC) and comorbid stage 3b chronic kidney disease (CKD). The discussion will address frontline and subsequent therapies, featuring data from EV-302, CheckMate 901, BLC2001, THOR, NORSE, and FORT-2.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical and surgical oncologists, urologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in treatment and management of patients with genitourinary cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select personalized treatments for patients with genitourinary malignancies based on disease and patient characteristics
• Implement biomarker testing in routine clinical practice to guide treatment decisions in the treatment of genitourinary malignancies

FACULTY

	Guru P. Sonpavde, MD Director of Genitourinary Medical Oncology & Phase I Clinical Research Christopher K. Glanz Chair for Bladder Cancer Research AdventHealth Cancer Institute Professor of Medicine, University of Central Florida Orlando, Florida
	Jonathan Anker, MD, PhD Clinical and Research Fellow Department of Hematology and Medical Oncology The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Guru P. Sonpavde, MD
Advisory Boards: Atkis, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Eli Lilly/Loxo Oncology, Gilead, Janssen, Kura Oncology, Merck, MS Pharma, Pfizer, PrecisCa, Scholar Rock, Seattle Genetics/Astellas, Vial
Consultant/Scientific Advisory Boards (SAB): Merck, Servier, Syapse, Syncorp
Research Support to Institution: Bristol Myers Squibb, EMD Serono, Jazz Therapeutics
Speaker: Astellas, Aveo, Bayer, Exelixis, Gilead, Janssen, Merck, Natera, Pfizer, Seagen
Writing/Editor Fees:DAVA Oncology, Onviv, Practice Update, Uptodate

Jonathan Anker, MD, PhD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 2, 2024 through November 2, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 31, 2024
Expiration date: July 31, 2025
Estimated time to complete activity: 90 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Recent developments in our understanding of molecular information, the tumor environment, and sequencing of therapies have allowed for greater personalization of therapy for patients with solid tumors and hematologic malignancies. In a practice that’s constantly evolving, keeping up to date with testing strategies, patient assessment, treatment selection and adverse event management can be a challenge.

This case-based archived symposium offers practical guidance for best practices across malignancies. The symposium archive includes algorithms for treatment used in the case discussion by expert faculty and any relevant updates from the 2024 Annual Meeting in early June. The focus will be practical, applicable information you can use in the clinic immediately.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologic oncologists, and oncology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select guideline-concordant treatment based upon best available evidence
• Incorporate best practices in molecular testing for patients diagnosed with cancer

FACULTY

	Jens Hillengass, MD, PhD Professor of Oncology Roswell Park Comprehensive Cancer Center Professor of Internal Medicine University at Buffalo Buffalo, New York
	Ayalew Tefferi, MD Hematologist Professor of Medicine Mayo Clinic
	Saad Z. Usmani, MD, MBA, FACP, FRCP, FASCO Chief of Myeloma Service Member, Memorial Sloan Kettering Cancer Center, New York, NY Attending Physician, Myeloma, Cellular Therapy and Adult BMT Professor of Medicine, Weill Cornell Medical College New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Jens Hillengass, MD, PhD has no real or apparent conflicts to disclose.

Ayalew Tefferi, MD has no real or apparent conflicts to disclose.

Saad Z. Usmani, MD, MBA, FACP, FRCP, FASCO
Consultation: AbbVie, Amgen, BMS, EdoPharma, Genentech, Gilead, GSK, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura
Research: Amgen, Array Biopharma, BMS, EdoPharm

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 31, 2024
Expiration date: July 31, 2025
Estimated time to complete activity: 90 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Recent developments in our understanding of molecular information, the tumor environment, and sequencing of therapies have allowed for greater personalization of therapy for patients with solid tumors and hematologic malignancies. In a practice that’s constantly evolving, keeping up to date with testing strategies, patient assessment, treatment selection and adverse event management can be a challenge.

This case-based archived symposium offers practical guidance for best practices across malignancies. The symposium archive includes algorithms for treatment used in the case discussion by expert faculty and any relevant updates from the 2024 Annual Meeting in early June. The focus will be practical, applicable information you can use in the clinic immediately.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologic oncologists, and oncology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select guideline-concordant treatment based upon best available evidence
• Incorporate best practices in molecular testing for patients diagnosed with cancer

FACULTY

	Matthew Cortese, MD, MPH Assistant Professor of Oncology Department of Medicine, Lymphoma Department of Cancer Genetics & Genomics Roswell Park Comprehensive Cancer Center Buffalo, New York
	Alex Niu, MD Staff Physician Assistant Professor of Oncology Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo, New York
	Danielle Wallace, MD Assistant Professor of Medicine Division of Hematology/Oncology University of Rochester Rochester, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Matthew J. Cortese, MD, MPH
Advisory Boards: ADC Therapeutics, AstraZeneca, Cellectar Biosciences, Synthekine, Inc.
Consultation: AbbVie, AstraZeneca, Secura Bio, Synthekine, Inc.
Speaker: OncLive, Targeted Oncology, Secura Bio

Alex Niu, MD has no real or apparent conflicts to disclose.

Danielle Wallace, MD
Consultant: Elsevier, Gather-ed

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 31, 2024
Expiration date: July 31, 2025
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Recent developments in our understanding of molecular information, the tumor environment, and sequencing of therapies have allowed for greater personalization of therapy for patients with solid tumors and hematologic malignancies. In a practice that’s constantly evolving, keeping up to date with testing strategies, patient assessment, treatment selection and adverse event management can be a challenge.

This case-based archived symposium offers practical guidance for best practices across malignancies. The symposium archive includes algorithms for treatment used in the case discussion by expert faculty and any relevant updates from the 2024 Annual Meeting in early June. The focus will be practical, applicable information you can use in the clinic immediately.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologic oncologists, and oncology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select guideline-concordant treatment based upon best available evidence
• Incorporate best practices in molecular testing for patients diagnosed with cancer

FACULTY

Jason Zittel, MD Assistant Professor of Hematology/Oncology Director of Myers Cancer Center Wilmot Cancer Institute University of Rochester Rochester, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Jason Zittel, MD has no real or apparent conflicts to disclose.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 31, 2024
Expiration date: July 31, 2025
Estimated time to complete activity: 120 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Recent developments in our understanding of molecular information, the tumor environment, and sequencing of therapies have allowed for greater personalization of therapy for patients with solid tumors and hematologic malignancies. In a practice that’s constantly evolving, keeping up to date with testing strategies, patient assessment, treatment selection and adverse event management can be a challenge.

This case-based archived symposium offers practical guidance for best practices across malignancies. The symposium archive includes algorithms for treatment used in the case discussion by expert faculty and any relevant updates from the 2024 Annual Meeting in early June. The focus will be practical, applicable information you can use in the clinic immediately.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologic oncologists, and oncology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select guideline-concordant treatment based upon best available evidence
• Incorporate best practices in molecular testing for patients diagnosed with cancer

FACULTY

	Renuka Iyer, MD Professor of Oncology Section Chief, Gastrointestinal Medical Oncology Vice-Chair of Faculty Recruitment & Retention Co-Director, Liver and Pancreas Tumor Program Department of Medicine Buffalo, New York
	Sarbajit Mukherjee, MD, MS Associate Professor of Oncology Department of Medicine, GI Medical Oncology Co-Leader, GI Translational Research Group Buffalo, New York
	Daniel Mulkerin, MD Professor, Hematology/Oncology Vice Chair Regional Operations, Department of Medicine Medical Director, Wilmot Cancer Institute University of Rochester Medical Center Rochester, New York
	Michael Pishvaian, MD, PhD Associate Professor Johns Hopkins University School of Medicine Baltimore, Maryland

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Renuka Iyer, MD
Consultant: Abbvie, AstraZeneca, Exelixis, Genentech, Incyte
Speaker: Intellisphere, NANETS

Sarbajit Mukerjee, MD, MS
Advisory Boards: BeiGene, Eisai, Merck
Research: Ipsen

Daniel Mulkerin, MD has no real or apparent conflicts to disclose.

Michael Pishvaian, MD, PhD
Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Steering Committee: Astellas, Renovo Rx
Stock: Perthera

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 31, 2024
Expiration date: July 31, 2025
Estimated time to complete activity: 90 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Recent developments in our understanding of molecular information, the tumor environment, and sequencing of therapies have allowed for greater personalization of therapy for patients with solid tumors and hematologic malignancies. In a practice that’s constantly evolving, keeping up to date with testing strategies, patient assessment, treatment selection and adverse event management can be a challenge.

This case-based archived symposium offers practical guidance for best practices across malignancies. The symposium archive includes algorithms for treatment used in the case discussion by expert faculty and any relevant updates from the 2024 Annual Meeting in early June. The focus will be practical, applicable information you can use in the clinic immediately.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologic oncologists, and oncology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select guideline-concordant treatment based upon best available evidence
• Incorporate best practices in molecular testing for patients diagnosed with cancer

FACULTY

	Matt Galsky, MD Professor of Medicine Icahn School of Medicine at Mount Sinai Director, Genitourinary Medical Oncology Associate Director, Translational Research Co-Leader, Cancer Clinical Investigation Program Tisch Cancer Institute New York, New York
	Brendan Guercio, MD Assistant Professor James P. Wilmot Cancer Institute University of Rochester Medical Center Rochester, New York
	Sindhuja Kadambi, MD, MS Assistant Professor Wilmot Cancer Institute University of Rochester Medical Center Strong Memorial Hospital Highland Hospital Rochester, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Matthew Galsky, MD
Consultant: Bristol Myers Squibb, Genentech, Janssen, Merck, Pfizer, SeaGen

Brendan Guercio, MD
Advisory Board: Jannsen
Investigator: Acrivon Therapeutics, Exelixis
Research: Genentech

Sindhuja Kadambi, MD, MS has no real or apparent conflicts to disclose.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 31, 2024
Expiration date: July 31, 2025
Estimated time to complete activity: 120 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Recent developments in our understanding of molecular information, the tumor environment, and sequencing of therapies have allowed for greater personalization of therapy for patients with solid tumors and hematologic malignancies. In a practice that’s constantly evolving, keeping up to date with testing strategies, patient assessment, treatment selection and adverse event management can be a challenge.

This case-based archived symposium offers practical guidance for best practices across malignancies. The symposium archive includes algorithms for treatment used in the case discussion by expert faculty and any relevant updates from the 2024 Annual Meeting in early June. The focus will be practical, applicable information you can use in the clinic immediately.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologic oncologists, and oncology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select guideline-concordant treatment based upon best available evidence
• Incorporate best practices in molecular testing for patients diagnosed with cancer

FACULTY

	Megan Baumgart, MD Association Professor of Medicine Division of Hematology/Oncology Program Director, Hematology/Oncology Fellowship Program Rochester, New York
	Grace Dy, MD Professor of Oncology Roswell Park Comprehensive Cancer Center Buffalo, New York
	Stephen Liu, MD Director, Thoracic Oncology Head, Developmental Therapeutics Georgetown University Lombardi Comprehensive Cancer Center Washington, DC
	Arpan Patel, MD Assistant Professor of Medicine – Thoracic Oncology Chief Quality Officer, Division of Hematology Oncology Associate Director for Informatics James P. Wilmot Cancer Institute University of Rochester Medical Center Rochester, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Megan Baumgart, MD has no real or apparent conflicts to disclose.

Grace Dy, MD
Consultant: Amgen, AstraZeneca, Bayer, Eli Lilly, Mirati, Novartis, Janssen, Regeneron

Stephen Liu, MD
Consultant: Abbvie, Amgen, AstraZeneca, Boehringer Ingehlheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Elevation, Genentech, Gilead, Guardant Health, Janssen, Jazz, Merck, Merus, Mirati, Novartis, Pfizer, RAPT, Regeneron, Revolution Medicines, Sanofi, Takeda
Research: Abbvie, Alkermes, AstraZeneca, Elevation, Ellipses, Genentech, Gilead, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma, RAPT, Turning Point Therapeutics

Arpan Patel, MD has no real or apparent conflicts to disclose.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 31, 2024
Expiration date: July 31, 2025
Estimated time to complete activity: 90 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Recent developments in our understanding of molecular information, the tumor environment, and sequencing of therapies have allowed for greater personalization of therapy for patients with solid tumors and hematologic malignancies. In a practice that’s constantly evolving, keeping up to date with testing strategies, patient assessment, treatment selection and adverse event management can be a challenge.

This case-based archived symposium offers practical guidance for best practices across malignancies. The symposium archive includes algorithms for treatment used in the case discussion by expert faculty and any relevant updates from the 2024 Annual Meeting in early June. The focus will be practical, applicable information you can use in the clinic immediately.

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologic oncologists, and oncology nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Select guideline-concordant treatment based upon best available evidence
• Incorporate best practices in molecular testing for patients diagnosed with cancer

FACULTY

	Susan Dent, MD Professor of Medicine Duke University Durham, North Carolina
	Shipra Gandhi, MD Assistant Professor of Oncology Department of Breast Medicine and Early Phase Clinical Trials Roswell Park Comprehensive Care Center Clinical Assistant Professor Department of Medicine Jacobs School of Medicine and Biomedical Sciences University at Buffalo (SUNY) Buffalo, New York
	Stefanie Graff, MD Director of Breast Oncology, Lifespan Cancer Institute Co-Lead, Breast Cancer Translational Disease Research Group Legorreta Cancer Center at Brown University Associate Professor of Medicine Warren Alpert Medical School of Brown University Providence, Rhode Island

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Susan Dent, MD
Advisory Boards: AstraZeneca, Gilead Sciences, Myocardial Solutions, Novartis, Pfizer

Shipra Gandhi, MD
Consultant: AstraZeneca, Hologic, MedPage Today, Novartis

Stephanie Graff, MD, FACP, FASCO
Consultant: AstraZeneca, Daiichi Sankyo, Genentech, Gilead Sciences, Lilly, Pfizer, SeaGen, Stemline/Menarini
Research Funding: AstraZeneca, Daiichi Sankyo, Lilly, Novartis
Stocks: HCA Healthcare

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: August 30, 2024
Expiration date: August 30, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

PROGRAM OVERVIEW

Schizophrenia is a psychiatric continuum that is now viewed as a complex neurobiologic disease involving a variety of neural networks that go beyond the well-studied dopaminergic pathways. It is now known that the hallmark and easily recognizable positive symptoms of schizophrenia — delusions, hearing voices — are often accompanied by equally devastating but less recognized symptoms in the cognitive and negative symptom domains. While excessive or dysregulated dopamine is still seen to be fundamental to the pathophysiology of this disease, recent research suggests the key to treating symptoms across all domains may lie in developing therapeutics that target different neurotransmitters.

These agents are now being tested in ongoing phase 3 clinical trials, and at least one may be approved this year. But most clinicians are unaware of the data that are emerging from these trials and are uncertain about how these agents work to target neurotransmitters and transform neurobiology. This MOA Challenge activity based on recently published articles and presentations at key psychiatry meetings will give psychiatrists and other clinicians who manage patients with schizophrenia the insight they need to understand and use these emerging treatments.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of psychiatrists, primary care and internal medicine physicians, and other clinicians who specialize in managing patients with schizophrenia, including nurse practitioners and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Differentiate between the concept of symptom domains and neurocognition in schizophrenia
• Identify the neural pathways and predominant neurotransmitters involved in the pathophysiology of schizophrenia symptom domains
• Recommend an emerging therapeutic agent for appropriately selected patients, based on efficacy and safety findings in clinical trials

FACULTY

Daniel C. Javitt, MD, PhD  Professor and Director, Division of Experimental Therapeutics Department of Psychiatry Columbia University Irving Medical Center New York, New York Director, Schizophrenia Research Nathan Kline Institute for Psychiatric Research Orangeburg, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Daniel C. Javitt, MD, PhD
Consultant: SK Life Science
Internal Speaker: Boehringer Ingelheim
Major Shareholder: NRx Pharmaceuticals
Monitoring Board Member: Biogen

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 30, 2024 through August 30, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: June 27, 2024
Expiration date: December 27, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity (ACCME) is provided by Integrity CE, LLC.
This activity (ACPE) is jointly provided by Global Education Group and Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from ALK-Abello, Inc.

PROGRAM OVERVIEW

Allergic rhinitis with or without conjunctivitis (AR/C) in children and adolescents is a commonly misunderstood, misdiagnosed, and mistreated condition. AR/C exerts a significant effect on quality of life and has deleterious effects on sleep, academic performance, family functioning, and involvement in outdoor activities. Fortunately, there have been advances in the diagnosis and treatment of AR/C that support improved diagnosis and care of patients with inadequate relief from symptom-relieving therapies, including broadly available specific immunoglobulin E (lgE) tests, advances in understanding of immune mechanisms, and newer allergen immunotherapies including oral tablet immunotherapy.

This program will review these important updates to provide clinicians with the knowledge and skills to provide care to children and adolescents with AR/C that is aligned with the latest evidence and best practices.

TARGET AUDIENCE

This educational activity has been designed for pediatricians, pediatric nurse practitioners, and pediatric physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Discuss the burden of symptoms of AR/C and the associated impacts on quality of life in children and adolescents
• Implement strategies for the early diagnosis and optimal assessment of AR/C in the pediatric setting
• Describe the role of allergy immunotherapy in the management of patients with AR/C
• Utilize available therapies to achieve optimal management of pediatric patients with AR/C

FACULTY

Michelle Yasharpour, MD Allergy and Immunology Cedars Sinai Medical Center Beverly Hills, California

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michelle Yasharpour, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 27, 2024 through December 27, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 65% or better and a completed activity evaluation form.

PHYSICIAN ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

CREDIT DESIGNATION

Global Education Group designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-24-023-H01-P)

This is a knowledge-based activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

For information about the accreditation (ACPE credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: July 26, 2024
Expiration date: July 26, 2025
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

PROGRAM OVERVIEW

Immunoglobulin A (IgA) nephropathy (IgAN) is a progressive autoimmune kidney disease and leading cause of kidney failure worldwide. Although there have been significant advances in understanding of its pathophysiology and continued development of new therapeutic approaches, challenges in IgAN management persist today, such as delayed diagnoses and available treatments inadequately slowing kidney function decline.
Join our esteemed faculty, Dr. Lafayette in this unique interactive activity that examines key strategies to achieve earlier diagnosis of IgAN, current clinical trial evidence regarding new and emerging therapies, and guidance on optimizing treatment.

TARGET AUDIENCE

This activity addresses the needs of nephrologists, specialty advanced practice providers, and other clinicians involved in the management of patients with IgAN, such as primary care providers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the pathophysiology of IgAN
• Apply clinical guideline recommendations to achieve earlier diagnosis of IgAN
• Summarize clinical trial evidence regarding new and emerging therapies for IgAN that can delay the onset of kidney failure and reduce the side effects of conventional treatments
• Outline a treatment plan for patients with IgAN with declining kidney function despite optimal standard of care and steroid therapy

FACULTY

Richard Lafayette, MD Professor of Medicine, Stanford University Medical Center Founder & Director, Stanford Glomerular Disease Center Stanford University Stanford, California

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Richard Lafayette, MD
Consultation Fees & Institutional Grants: Alexion, Amgen, BeiGene, Calliditas Therapeutics, Novartis, Omeros,‏‏ Otsuka, Roche, Travere Therapeutics, Vera Therapeutics, Visterra
Data Safety Monitoring Boards: Amgen, Cara Therapeutics

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 26, 2024 through July 26, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 70% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: June 21, 2024
Expiration date: June 21, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

PROGRAM OVERVIEW

Discoveries about the pathogenesis of pulmonary arterial hypertension (PAH) revealed key molecular pathways that could be targeted to treat this cardiopulmonary disorder. A multitude of new therapies with differing mechanisms of action began to appear in the late 1990s and experts discovered that combination treatments were key to extending life. Today, 5-year survival rates approach 70%.

Premiere clinical guidelines on diagnosing and managing PAH were recently revised and updated and in March 2024, two new treatment choices were approved by the FDA — a fixed-dose, single-tablet combination of the two drug classes that are recommended as initial treatment for most patients, and a first-in-class transforming growth factor inhibitor.

Join PAH expert Dr. John J. Ryan for this on-demand data dive activity that explores recent guideline changes, newly approved treatments, and freshly released data on emerging therapies.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of cardiologists, pulmonologists, rheumatologists, and other physicians, including those in primary care and internal medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with PAH.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Assess new and revised recommendations for the management of PAH outlined in the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
• Integrate investigational treatments (when available) into PAH treatment selections based on recently released or forthcoming clinical trial findings

FACULTY

John J. Ryan, MD, MB, BCh, BAO Professor, University of Utah Director, Pulmonary Hypertension Comprehensive Care Center Director, Cardiovascular Medicine Fellowship Program Interim Chief of General Cardiology University of Utah Hospital University of Utah School of Medicine Salt Lake City, Utah

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

John J. Ryan, MD, MB, BCh, BAO
Advisor, Researcher, Speaker: Johnson and Johnson, Kiniksa Pharmaceuticals, Merck, United Therapeutics

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of June 21, 2024 through June 21, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: May 24, 2024
Expiration date: August 24, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from AstraZeneca Pharmaceuticals, Lilly, Novartis Pharmaceuticals Corporation, and Seagen, Inc.

PROGRAM OVERVIEW

This case focuses on a young patient diagnosed with triple-negative breast cancer (TNBC) who completes chemotherapy, radiation, and 10 years of endocrine therapy. At that point she has progression.

The faculty provide their approach to choosing the best treatment strategy for this patient. Trials discussed include: KEYNOTE-355, DESTINY-Breast04, and ASCENT.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in the treatment and management of patients with breast cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Integrate genomic, immunogenic, and proteomic aberration assessments to guide treatment decisions
• Individualize therapeutic regimens based on the molecular profile of tumors and patient characteristics
• Implement supportive care strategies to mitigate and manage unique toxicities associated with recently approved and emerging targeted therapies

FACULTY

	Margaret Gatti-Mays, MD, MPH  The Division of Medical Oncology  The Ohio State University  Comprehensive Cancer Center Cleveland, Ohio
	Nerea Lopetegui-Lia, MD Hematology/Medical Oncology Fellow Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Margaret Gatti-Mays, MD, MPH
Advisor: GE Health

Nerea Lopetegui-Lia, MD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of May 24, 2024 through August 24, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: March 13, 2024
Expiration date: March 13, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity CE, LLC.
This CE activity for AANP credit is jointly provided by Global Education Group and Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from Sanofi and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

Uncontrolled atopic dermatitis (AD) can have dire, lifelong consequences for children and their families. However, medical science has developed several treatments that target the molecular drivers of this immuno-inflammatory skin disease that has negative effects on overall health and quality of life. Join AD expert Dr. Peter Lio for this on-demand video activity about systemic therapeutic options for infants, children, and adolescents who are affected by moderate-to-severe AD.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with atopic dermatitis.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Characterize the extracutaneous consequences of uncontrolled moderate-to-severe atopic dermatitis (AD) on patients and parents/caregivers
• Delineate the immuno-inflammatory molecular catalysts that underly moderate or severe manifestations of pediatric AD
• Describe how to integrate systemic therapeutic options for infants, children, and adolescents who are affected by moderate-to-severe AD

FACULTY

Peter Lio, MD, FAAD Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai Clinical Assistant Professor of Dermatology & Pediatrics Northwestern University Feinberg School of Medicine Founding Director, Chicago Integrative Eczema Center Founding Partner, Medical Dermatology Associates of Chicago Chicago, Illinois

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC and Global Education Group requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

Peter Lio, MD, FAAD
Advisory Boards: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KPAway), Burt’s Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, LEO, Level Ex, Lipidor AB, L’Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, YobeeCare
Patent Holder: Theraplex AIM (patent pending)
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Speaker: AbbVie, Eli Lilly, Galderma, Incyte, LEO, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme
Stock Options: Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences, LearnSkin,
Micreos, YobeeCare

The Integrity CE, LLC and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of March 13, 2024 through March 13, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 67% or better and a completed activity evaluation form.

ACCREDITATION

Physician Continuing Education

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity CE, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hours (which includes 0.0 hour(s) of pharmacology).

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: April 8, 2024
Expiration date: April 8, 2025
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Sanofi.

PROGRAM OVERVIEW

Every 5 minutes, someone is diagnosed with multiple sclerosis (MS), according to the Multiple Sclerosis International Federation’s Atlas of MS. Along with 85% of other newly diagnosed patients with MS, they will be diagnosed with relapsing-remitting MS (RRMS), one of the four MS subtypes.

In 2024, five emerging Bruton’s tyrosine kinase (BTK) inhibitors are undergoing late-phase clinical investigation for MS, but most clinicians are likely unaware of their place in the development pipeline and the clinical data regarding their use in MS. This Deep Dive activity into recently published or released data about BTK inhibitors in MS will convey critical information to neurologists and other clinicians about this innovative approach to MS management.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of neurologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians who manage patients with MS.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Identify the role of BTK as a therapeutic target in the immunopathogenesis of MS
• Explain the mechanism of action of BTK inhibitors when used for MS
• Outline ideas for incorporating BTK inhibitors (when FDA approved) into therapeutic options for MS based on new and emerging efficacy and safety findings from clinical trials

FACULTY

Daniel S. Reich, MD, PhD Senior Investigator and Chief Translational Neuroradiology Section National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH), USA​

He appears here in his private capacity, as an approved Outside Activity, and the views and opinions here do not represent those of NINDS or NIH.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Daniel S. Reich, MD, PhD
NIH Cooperative Research and Development Agreements: Abata Therapeutics, Sanofi

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period April 8, 2024 through April 8, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: March 15, 2024
Expiration date: September 15, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

PROGRAM OVERVIEW

EoE is an immuno-inflammatory disease that affects people of all age groups (including children) and is often triggered by certain foods or aeroallergen microbes. The prevalence of EoE has increased over the past few decades, and few clinicians — including specialists in gastroenterology — are able to recognize the signs and symptoms of this disease. Patients with EoE are often misdiagnosed or go without a correct diagnosis (and appropriate treatment) for several years. What is known to be the appropriate treatment has historically comprised a wide variety of dietary interventions that can be difficult to adhere to and off-label pharmacologics that have mixed efficacy. Since the approval of dupilumab, the first drug ever to be given an EoE indication, treatment options have expanded, offering a new landscape for gastroenterologists, allergists, and other clinicians who manage patients with EoE by giving them a new way to personalize treatment approaches for both their adult and pediatric patients.

Whether you work in primary care, pediatrics, or in gastroenterology, follow along with Drs. Chang and Chehade to improve the diagnosis and management of patients with EoE. This self-paced course will allow for a unique learning path based on your current knowledge and skill level and enhance understanding of EoE disease burden and clinical indicators of EoE, improve rates of referral, and assist in the creation of more individualized treatment plans.

TARGET AUDIENCE

This activity addresses the needs of gastroenterologists, pediatric gastroenterologists, specialty advanced practice providers, pediatricians and pediatric nurse practitioners, and internal medicine clinicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Identify signs, symptoms, and clinical indicators of EoE to facilitate referral for specialist evaluation or earlier diagnosis
• Assess the disease burden of EoE and the weight of its effect on physical and psychological quality of life
• Employ strategies for individualized treatment and monitoring of treatment response
• Incorporate new or emerging EoE treatments based on efficacy and safety findings from clinical trials

FACULTY

	Joy W. Chang, MD MS Assistant Professor of Internal Medicine Division of Gastroenterology University of Michigan Ann Arbor, Michigan
	Mirna Chehade, MD, MPH, AGAF, FAAAAI Professor of Pediatrics and Medicine Founding Director, Mount Sinai Center for Eosinophilic Disorders Icahn School of Medicine at Mount Sinai New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Mirna Chehade, MD, MPH
Consultant: Adare/Ellodi, Allakos, AstraZeneca, Bristol Myers SquibbNexstone Immunology, Phathom, Recludix Pharma, Regeneron, Sanofi, Shire/Takeda,
Research Funding: Adare/Ellodi, Allakos, AstraZeneca Regeneron, Bristol Myers Squibb, Danone, Shire/Takeda

Joy W. Chang, MD MS
Consultant: Sanofi-Regeneron
Speaker: Sanofi-Regeneron

Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of March 15, 2024 through September 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc. you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: February 28, 2024
Expiration date: February 28, 2025
Estimated time to complete activity: 75 minutes

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity CE, LLC.
This CE activity for AANP credit is jointly provided by Global Education Group and Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from ALK-Abello, Inc.

PROGRAM OVERVIEW

Allergic rhinitis usually presents in early childhood and is caused by an immunoglobulin E (IgE)-mediated reaction to various indoor and outdoor allergens. In this video activity, Dr. Michael Blaiss will discuss the burden of symptoms of allergic rhinitis/rhinoconjunctivitis (AR/C), how to implement strategies for early diagnosis, and the role of allergy immunotherapy in the management of patients with AR/C.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pediatric allergists, allergists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with allergic rhinitis.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Discuss the burden of symptoms of AR/C and the associated impacts on quality of life in children and adolescents
• Discuss how to implement strategies for the early diagnosis and optimal assessment of AR/C in the pediatric setting
• Describe the role of allergy immunotherapy in the management of patients with AR/C
• Discuss how to utilize available therapies to achieve optimal management of pediatric patients with AR/C

FACULTY

Michael S. Blaiss, MD, FAAAAI, FACAAI Clinical Professor of Pediatrics Medical College of Georgia at Augusta University Augusta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

Michael S. Blaiss, MD, FAAAAI, FACAAI
Consulting Fees: ALK-Abello, Inc., AnaptysBio, AstraZeneca, Bellus, GlaxoSmithKline, Hippo Dx, Lanier Biotherapeutics, Merck, Prollergy, Regeneron, Sanofi
Speaker’s Bureaus: ALK-Abello Inc., Merck, Regeneron, Sanofi

The Integrity CE, LLC and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of February 28, 2024 through February 28, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.

ACCREDITATION

Physician Continuing Education

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity CE, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hours (which includes 0.125 hour(s) of pharmacology).

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

For information about AANP approval of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: February 15, 2024
Expiration date: August 15, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

PROGRAM OVERVIEW

Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. An increased understanding of the pathophysiology of COPD, particularly the eosinophilic phenotype, has shown that the cytokines IL-4, IL-5, and IL-13 play a critical part in the inflammatory process. IL-33 also appears to be involved in this process. The discovery of these cytokines and the role they have in T2 inflammation points to potential therapeutic targets, and predictive biomarkers for treatment response and disease progression. Three newly approved therapies for asthma that target IL-4, IL-5, and/or IL-13 (mepolizumab, benralizumab, and dupilumab) are now in trials for COPD, while iItepekimab is under investigation for both asthma and COPD. Available evidence to date shows the promise for a biologic to potentially be approved and available for the treatment of COPD in the near future. In this activity, Drs. Surya Bhatt and Nicola Hanania will engage in a dynamic discussion and walk you through a series of interactive case-based decision points to help you learn more about T2 inflammation in COPD and how to best manage these patients given currently available data.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of US pulmonologists, specialty advanced practice providers (APPs), and internal medicine clinicians.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the pathologic evidence for T2 inflammation in COPD and potential treatment targets
• Identify available biomarkers that signal T2 inflammation in COPD and may predict disease progression or treatment response
• Review available clinical data supporting the use of targeted biologics in the management of patients with COPD
• Develop management plans for patients with COPD based on individual patient characteristics

FACULTY

	Surya P. Bhatt, MD Medical Director Pulmonary Function and Exercise Physiology Lab University of Alabama–Birmingham Birmingham, Alabama
	Nicola Alexander Hanania, MD Professor of Medicine Director, Airways Clinical Research Center Baylor College of Medicine Houston, Texas

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Surya P. Bhatt, MD
Advisory Board: Boehringer Ingelheim, GSK, Regeneron, Sanofi
Consulting: Boehringer Ingelheim, Sanofi
Research Support: Nuvaira, Sanofi, Genentech

Nicola Alexander Hanania, MD
Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Sanofi, Teva
Research Support: AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, Sanofi, Teva
Speaker: Sanofi

Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of February 15, 2024 through August 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 65% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc. you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: February 5, 2024
Expiration date: August 5, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Although immunotherapy has dramatically expanded the treatment landscape for a range of advanced cancers, there are several subtypes, including certain breast and lung cancers, that remain resistant to standard treatments and for which treatment options are limited. As a result, many patients continue to experience declining response rates, disease control, and quality of life. Nevertheless, efforts to identify novel approaches for addressing these significant unmet needs are ongoing. One approach that has shown a great deal of promise and has garnered significant attention recently is the use of antibody-drug conjugates (ADCs) that target Trop-2, a transmembrane glycoprotein that is upregulated in many cancers. By taking advantage of monoclonal antibodies selective for Trop-2, these agents enable the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells. There is currently only one Trop-2 ADC that has been approved by the FDA for TNBC and HR+/HER2- BC. However, evidence continues to emerge in support of the use of multiple Trop-2 ADCs in not only these cancers, but others as well.

Join Drs. Jason Porter and Lee Schwartzberg as they dive deeper into the most relevant data on Trop-2 ADCs and help clinicians incorporate Trop-2-targeted ADCs into evidence-based treatment plans for patients with TNBC, HR+/HER2- BC, and NSCLC.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of community oncologists and advanced practice providers involved in the care of patients with breast or lung cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the rationale for Trop-2 ADCs for the treatment of breast and lung cancer
• Review current and emerging evidence supporting the use of Trop-2 ADCs for the treatment of TNBC, HR+/HER2- BC, and NSCLC
• Design evidence-based plans for the treatment of TNBC, HR+/HER2- BC, and NSCLC employing Trop-2 ADCs

FACULTY

	Jason Porter, MD Medical Oncologist/Hematologist West Cancer Center and Research Institute Memphis, Tennessee
	Lee Schwartzberg, MD, FACP Professor of Clinical Medicine University of Nevada – Reno Chief, Medical Oncology/Hematology William N. Pennington Cancer Institute at Renown Health Reno, Nevada

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Jason Porter, MD
Consultant: Amgen, Bristol Myers Squibb, G1 Therapeutics Inc., Jazz, Merck, Mirati, Novartis, Regeneron Pharmaceuticals, Inc.
Speaker: Amgen, Bristol Myers Squibb, G1 Therapeutics Inc., Jazz, Merck, Mirati, Novartis, Regeneron Pharmaceuticals, Inc.

Lee Schwartzberg, MD, FACP
Consultant: AstraZeneca, Daiichi Sankyo, Genentech, Napo, Novartis, Seagen
Speaker: AstraZeneca, Daiichi Sankyo, Merck, Novartis, Pfizer, Seagen

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of February 5, 2024 through August 5, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 60% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 15, 2024
Expiration date: April 15, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This educational activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

Stage III non-small cell lung cancer (NSCLC) is a heterogenous disease that is typically treated with multimodal therapeutic approaches, which may include systemic therapies, radiotherapy, and surgery. Individualizing treatment strategies for patients with stage III NSCLC requires accurate clinical and pathological staging. The treatment journey of patients with stage III NSCLC has evolved rapidly over the last few years with improved staging approaches and approval of consolidation immunotherapy following concurrent chemoradiotherapy (cCRT).

Pretreatment multidisciplinary team discussion is crucial in defining the most optimal treatment approach for each patient. This activity will feature Dr. Ticiana Leal sharing her thoughts on the implications for cCRT and consolidation with durvalumab in the perioperative treatment paradigm.

TARGET AUDIENCE

This educational activity was developed to meet the professional needs of medical, surgical, and radiation oncologists, along with other healthcare providers involved in the treatment and management of patients with lung cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Evaluate the efficacy and safety data of current and emerging therapeutic approaches for patients with unresectable stage III NSCLC

FACULTY CHAIR

Ticiana Leal, MD Associate Professor Department of Hematology/Oncology Director, Thoracic Medical Oncology Program Winship Cancer Institute Emory University Atlanta, Georgia

FACULTY DISCUSSANTS

	Aakash Desai, MD Assistant Professor University of Alabama at Birmingham Birmingham, Alabama
	Kristin A. Higgins, MD Professor and Vice Chair of Clinical Research Department of Radiation Oncology Winship Cancer Institute Emory University Atlanta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aakash Desai, MD
Consultant: Amgen, AstraZeneca, Foundation Medicine, Sanofi

Kristin A. Higgins, MD
Advisory Boards: AstraZeneca, Janssen Pharmaceuticals
Consultant: Picture Health
Funded Research: Jazz Pharmaceuticals

Ticiana Leal, MD, does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 15, 2024 through April 15, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 11, 2024
Expiration date: January 11, 2025
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in multiple myeloma and precursor conditions released at the recent meeting in San Diego, led by expert faculty, Dr. Ola Landgren and Dr. Saad Usmani. The following abstracts will be covered:

• Relapsed/Refractory Multiple Myeloma (RRMM)
  • Oral Abstract 1021 – The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
  • Oral Abstract 542 – Real-World Results: Treatment Patterns and Clinical Outcomes Among Triple-Class– and BCMA-Exposed Multiple Myeloma
  • Oral Abstract 91 – Real-World Outcomes With Teclistamab for Heavily-Pretreated Relapsed-Refractory Multiple Myeloma
  • Oral Abstract 1023 – Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
  • Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
• Newly-Diagnosed Multiple Myeloma (NDMM)
  • Oral Abstract 210 – Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study
  • Oral Abstract LBA-1 – PERSEUS  – Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
  • Oral Abstract 4 – Iskia esults of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and hematologists, as well as other healthcare providers that treat and manage patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options
• Identify patients that could potentially benefit from referral to a clinical trial

FACULTY

	Ola Landgren, MD, PhD Chief of Myeloma Professor of Medicine Director, Slyvester Myeloma Institute University of Miami Miami, Florida
	Saad Usmani, MD, MBA, FACP, FRCP Chief of Myeloma Service Member, Memorial Sloan Kettering Cancer Center Attending Physician, Myeloma, Cellular Therapy and Adult BMT Professor, Weill Cornell Medical College – Cornell University New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Ola Landgren, MD, PhD
Advisory Boards: Adaptive Biotech, Amgen, Bristol Myers Squibb, Janssen, Pfizer
Grant Support: Amgen, Janssen, Karyopharm, Takeda

Saad Usmani, MD, MBA, FACP, FRCP
Advisory Boards: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
Research Funding: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 11, 2024 through January 11, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 72% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 8, 2024
Expiration date: January 8, 2025
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

Prurigo nodularis (PN) is a dermatologic disease that starts at a deep, neuro-immune molecular level and nothing applied to or done to the top of the skin will ever bring relief. The only thing that will work to tame the itch are targeted treatments that address the underlying type 2 immuno-inflammatory molecular drivers of this disease. Fortunately, patients with PN now have an FDA-approved treatment option that does just that, and other treatments in late-phase clinical development may be close behind. Join our expert faculty as they explore PN and its new and emerging treatment options.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of dermatologists as well as nurse practitioners and physician assistants involved in the management of patients with PN.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Characterize the burden of disease imposed by PN, including unbearable itch, diminished quality of life, and psychological distress
• Describe the pathogenesis and pathophysiology of PN
• Discuss evidence-based management strategies when assessing and treating PN
• Integrate new and emerging therapies into treatment regimens for appropriately selected patients with PN

FACULTY CHAIR

Shawn G. Kwatra, MD  Associate Professor of Dermatology Department of Dermatology Director, Johns Hopkins Itch Center Johns Hopkins University School of Medicine Baltimore, Maryland

FACULTY

Sarina Elmariah, MD, PhD, MPH Associate Professor, Dermatology Director, UCSF Center for Itch and Neurosensory Disorders University of California San Francisco San Francisco, California

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Sarina Elmariah, MD, PhD, MPH
Advisory Board: Bellus Health, Galderma, Lilly, Pfizer, Sanofi-Regeneron, Trevi Therapeutics
Stocks: New Frontier Bio

Shawn G. Kwatra, MD
Consultant: AbbVie, Acrutis Biotherapeutics, Aslan Pharmaceuticals, Castle Bioscience, Celldex Therapeutics, Novartis
Investigator: Incyte, Pfizer, Regeneron, Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 8, 2024, through January 8, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 1, 2023
Expiration date: March 31, 2024
Estimated time to complete activity: 30 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Treatment with biologic therapy as compared with maintenance corticosteroids (oral or high-dose inhaled) has consistently been shown to reduce disease burden among a wide range of individuals with moderate-to-severe asthma. Nevertheless, a significant subset of patients treated with biologics continues to experience poor asthma control and a high burden of disease, raising important questions regarding how to optimize the use of available therapies. Join our esteemed clinician faculty as they discuss the selection of appropriate initial biologic therapy for patients with moderate-to-severe asthma to improve health outcomes.

TARGET AUDIENCE

This educational activity has been designed for US allergists, pulmonologists, advanced practice providers in allergy and pulmonary settings, and internal medicine clinicians.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Select the most appropriate biologic for patients with uncontrolled asthma based on comprehensive assessment of individual characteristics

FACULTY CO-CHAIRS

	Linda B. Ford, MD, FAAAAI, FACAAI, AE-C Clinical Assistant Professor Department of Pediatrics University of Nebraska Medical Center President and CEO The Asthma & Allergy Center, PC Omaha, Nebraska
	Reynold A. Panettieri, Jr., MD Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Rutgers University Emeritus Professor of Medicine, University of Pennsylvania New Brunswick, New Jersey

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Linda B. Ford, MD, FAAAAI, FACAAI, AE-C
Independent Contractor: Allergy Therapeutics, AstraZeneca, Bellus, Chiesi, Enanta, Genentech, Koneksa, Regeneron, Sanofi, Suzhou

Reynold A. Panettieri, Jr., MD
Advisor: Praesidia Biotherapies Inc.
Advisory Board: AstraZeneca, Genentech, RIFM
Consultant: AstraZeneca, RIFM, TEVA
Research Grants: ACTIV-1, AgoMab, AstraZeneca, Janssen, Medimmune, RIFM, TEVA, Vault Health
Speaker: AstraZeneca, Merck & Co., Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 1, 2023 through March 31, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 1, 2023
Expiration date: March 31, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Treatment with biologic therapy as compared with maintenance corticosteroids (oral or high-dose inhaled) has consistently been shown to reduce disease burden among a wide range of individuals with moderate-to-severe asthma. Nevertheless, a significant subset of patients treated with biologics continue to experience poor asthma control and a high burden of disease, raising important questions regarding how to optimize the use of available therapies. Join our esteemed clinician faculty as they discuss evaluating biologic therapy responses for patients with moderate-to-severe asthma to improve health outcomes.

TARGET AUDIENCE

This educational activity has been designed for US allergists, pulmonologists, advanced practice providers in allergy and pulmonary settings, and internal medicine clinicians.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Describe current recommendations for assessment of biologic therapy after initiation and factors that may predispose patients to biologic stopping or switching in the first year of therapy

FACULTY CO-CHAIRS

	Linda B. Ford, MD, FAAAAI, FACAAI, AE-C Clinical Assistant Professor Department of Pediatrics University of Nebraska Medical Center President and CEO The Asthma & Allergy Center, PC Omaha, Nebraska
	Reynold A. Panettieri, Jr., MD Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Rutgers University Emeritus Professor of Medicine, University of Pennsylvania New Brunswick, New Jersey

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Linda B. Ford, MD, FAAAAI, FACAAI, AE-C
Independent Contractor: Allergy Therapeutics, AstraZeneca, Bellus, Chiesi, Enanta, Genentech, Koneksa, Regeneron, Sanofi, Suzhou

Reynold A. Panettieri, Jr., MD
Advisor: Praesidia Biotherapies Inc.
Advisory Board: AstraZeneca, Genentech, RIFM
Consultant: AstraZeneca, RIFM, TEVA
Research Grants: ACTIV-1, AgoMab, AstraZeneca, Janssen, Medimmune, RIFM, TEVA, Vault Health
Speaker: AstraZeneca, Merck & Co., Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 1, 2023 through March 31, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: September 1, 2023
Expiration date: March 31, 2024
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Treatment with biologic therapy as compared with maintenance corticosteroids (oral or high-dose inhaled) has consistently been shown to reduce disease burden among a wide range of individuals with moderate-to-severe asthma. Nevertheless, a significant subset of patients treated with biologics continue to experience poor asthma control and a high burden of disease, raising important questions regarding how to optimize the use of available therapies. Join our esteemed clinician faculty as they discuss long-term biologic treatment data for patients with moderate-to-severe asthma.

TARGET AUDIENCE

This educational activity has been designed for US allergists, pulmonologists, advanced practice providers in allergy and pulmonary settings, and internal medicine clinicians.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Review long-term efficacy and safety data of available biologics reported in real-world and open-label extension trials

FACULTY CO-CHAIRS

	Linda B. Ford, MD, FAAAAI, FACAAI, AE-C Clinical Assistant Professor Department of Pediatrics University of Nebraska Medical Center President and CEO The Asthma & Allergy Center, PC Omaha, Nebraska
	Reynold A. Panettieri, Jr., MD Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Rutgers University Emeritus Professor of Medicine, University of Pennsylvania New Brunswick, New Jersey

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Linda B. Ford, MD, FAAAAI, FACAAI, AE-C
Independent Contractor: Allergy Therapeutics, AstraZeneca, Bellus, Chiesi, Enanta, Genentech, Koneksa, Regeneron, Sanofi, Suzhou

Reynold A. Panettieri, Jr., MD
Advisor: Praesidia Biotherapies Inc.
Advisory Board: AstraZeneca, Genentech, RIFM
Consultant: AstraZeneca, RIFM, TEVA
Research Grants: ACTIV-1, AgoMab, AstraZeneca, Janssen, Medimmune, RIFM, TEVA, Vault Health
Speaker: AstraZeneca, Merck & Co., Sanofi

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 1, 2023 through March 31, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: January 9, 2024
Expiration date: January 9, 2025
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharpe & Dohme, LLC.

PROGRAM OVERVIEW

This activity will provide context and insight on the latest data in breast cancer released at the recent meeting in San Antonio, led by expert faculty. The following abstracts will be covered:

• CAPItello-291
• TROPION-Breast01
• Real-world Outcomes With ADCs for HER2-low Metastatic Breast Cancer
• KEYNOTE-756
• KEYNOTE-522
• neoMono
• Neo-N
• ALEXANDRA/IMpassion030
• APTneo
• KATHERINE
• HER2CLIMB-02
• HERB TEA
• AVIATOR
• APHINITY
• monarchE
• NATALEE
• PALLAS

TARGET AUDIENCE

This educational activity was designed for community-based medical oncologists and other healthcare providers that treat and manage patients with breast cancer.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options for patients with breast cancer

FACULTY

	Aditya Bardia, MD Director, Breast Cancer Research Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts
	Maryam Lustberg, MD, MPH Director, Center for Breast Cancer Smillow Cancer Hospital and Yale Cancer Center Chief, Breast Medical Oncology Yale Cancer Center New Haven, Connecticut
	Paolo Tarantino, MD Advanced Research Fellow Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aditya Bardia, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi
Research Grants: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Sanofi

Maryam Lustberg, MD, MPH
Consultant: AstraZeneca, Eli Lily, Gilead, Novartis, Pfizer

Paolo Tarantino, MD
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Novartis, Roche
Research Funding: AstraZeneca
Speaker: AstraZeneca, Daiichi Sankyo

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 9, 2024 through January 9, 2025, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 22, 2023
Expiration date: December 22, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease that is typically treated with multimodal therapeutic approaches, which may include systemic therapies, radiotherapy, and surgery. Individualizing treatment strategies for patients with stage III NSCLC requires accurate clinical and pathological staging. The treatment journey of patients with stage III NSCLC has evolved rapidly over the last few years with improved staging approaches and approval of consolidation immunotherapy following concurrent chemoradiotherapy (cCRT).

Pretreatment multidisciplinary team discussion is crucial in defining the most optimal treatment approach for each patient. This activity will feature a multidisciplinary panel of three expert faculty discussing the current standard of care and the quickly moving science that is changing the treatment paradigm for patients with stage III unresectable NSCLC. The discussion will center around the treatment of a typical case and focus on optimal treatment selection, the challenges faced, and each faculty’s insight on their approach to treatment.

TARGET AUDIENCE

This educational activity was developed to meet the professional needs of medical, surgical, and radiation oncologists, along with other healthcare providers involved in the treatment and management of patients with lung cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Implement guideline recommended diagnostic and staging methodologies and utilize pretreatment multidisciplinary teams to individualize treatment plans for patients with unresectable stage III NSCLC
• Evaluate the efficacy and safety data of current and emerging therapeutic approaches for patients with unresectable stage III NSCLC
• Apply effective monitoring and management strategies for unique adverse events associated with chemoradiotherapy and consolidation immune checkpoint inhibitor treatment

FACULTY CO-CHAIRS

	Kristin A. Higgins, MD Professor and Vice Chair of Clinical Research Department of Radiation Oncology Winship Cancer Institute Emory University Atlanta, Georgia
	Onkar Khullar, MD, MSc, FACS  Associate Professor Department of Surgery Winship Cancer Institute Emory University Atlanta, Georgia
	Ticiana Leal, MD Associate Professor Department of Hematology/Oncology Director, Thoracic Medical Oncology Program Winship Cancer Institute Emory University Atlanta, Georgia

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Kristin A. Higgins, MD
Advisory Boards: AstraZeneca, Janssen Pharmaceuticals
Consultant: Picture Health
Funded Research: Jazz Pharmaceuticals

Onkar Khullar, MD, MSc, FACS, does not have any financial relationships or relationships to products or devices with ineligible companies.

Ticiana Leal, MD, does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 22, 2023 through December 22, 2024, participants must:

• Read the learning objectives
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe^® Flash^® Player 10

• Adobe^® Flash^® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 21, 2023
Expiration date: December 21, 2024
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

PROGRAM OVERVIEW

Characterized by severe flares of painful, pruritic, pus-filled blisters, generalized pustular psoriasis (GPP) is a rare dermatologic disorder that many dermatologists have never seen…at least not that they realized. Historically thought of as a severe form of plaque psoriasis (PsO), recent insights into the pathogenesis of GPP show it to be a distinct immuno-inflammatory disease driven by overactivity of the IL-36 pathway.

Join GPP experts Dr. Mark Lebwohl and Dr. Boni Elewski to find out what dermatologists and other healthcare professionals need to know about the pathogenesis of GPP, the mechanism of action of IL-36 receptor antagonists, and how to recognize, diagnose, and manage patients with this inflammatory cutaneous disease.

TARGET AUDIENCE

This educational activity is designed for dermatologists and other healthcare professionals involved in the management of rare dermatologic conditions such as GPP, including primary care physicians, nurse practitioners, and physician assistants.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Identify patient characteristics, common comorbidities, and frequently observed triggers that should raise the index of suspicion for GPP and lead to a timelier diagnosis
• Describe the pathogenesis of GPP and the mechanism of action of interleukin-36 (IL-36) receptor antagonists
• Incorporate new and emerging IL-36 receptor inhibitors to treat and prevent GPP flares based on recent clinical trial findings
• Develop a multidisciplinary, patient-centric strategy to address the cutaneous and extracutaneous disease burden of GPP